Alkem Laboratories Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Alkem Laboratories is de winst gegroeid met een gemiddeld jaarlijks percentage van 6.9%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 13.3%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 10.5% per jaar. Het rendement op eigen vermogen van Alkem Laboratories is 18.1%, en het heeft een nettomarge van 16.5%.
Belangrijke informatie
6.9%
Groei van de winst
6.9%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 17.5% |
| Inkomstengroei | 10.5% |
| Rendement op eigen vermogen | 18.1% |
| Nettomarge | 16.5% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models
Nov 16
Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching
Nov 15What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You
Sep 24Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Sep 03Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Aug 13Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 27Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00
Jul 13Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jun 27Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00
Jun 13Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Jun 01Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)
May 22Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 13Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects
Jan 17We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease
Dec 27Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Sep 14Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Aug 02Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Jul 07Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
May 22We Think Alkem Laboratories (NSE:ALKEM) Can Stay On Top Of Its Debt
Mar 27Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Dec 26These 4 Measures Indicate That Alkem Laboratories (NSE:ALKEM) Is Using Debt Reasonably Well
Sep 20Alkem Laboratories' (NSE:ALKEM) Dividend Is Being Reduced To ₹4.00
Jul 27Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 13Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Jun 11Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
May 23Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Mar 06Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Feb 21Opbrengsten en kosten
Hoe Alkem Laboratories geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 128,319 | 21,223 | 31,227 | 0 |
| 30 Jun 24 | 127,317 | 20,542 | 30,675 | 0 |
| 31 Mar 24 | 126,676 | 17,958 | 30,329 | 0 |
| 31 Dec 23 | 126,344 | 15,732 | 30,394 | 0 |
| 30 Sep 23 | 123,514 | 14,329 | 29,926 | 0 |
| 30 Jun 23 | 119,906 | 11,433 | 30,081 | 0 |
| 31 Mar 23 | 115,993 | 9,842 | 29,726 | 0 |
| 31 Dec 22 | 111,805 | 10,208 | 27,081 | 0 |
| 30 Sep 22 | 107,586 | 10,917 | 26,536 | 0 |
| 30 Jun 22 | 104,792 | 13,051 | 25,772 | 0 |
| 31 Mar 22 | 106,342 | 16,456 | 25,769 | 0 |
| 31 Dec 21 | 103,425 | 17,780 | 22,660 | 0 |
| 30 Sep 21 | 100,416 | 17,033 | 22,048 | 0 |
| 30 Jun 21 | 96,044 | 16,311 | 21,183 | 0 |
| 31 Mar 21 | 88,650 | 15,850 | 19,807 | 0 |
| 31 Dec 20 | 87,218 | 15,338 | 21,217 | 0 |
| 30 Sep 20 | 85,971 | 14,648 | 21,076 | 0 |
| 30 Jun 20 | 84,984 | 13,636 | 20,892 | 0 |
| 31 Mar 20 | 83,444 | 11,271 | 20,853 | 0 |
| 31 Dec 19 | 81,484 | 11,057 | 20,347 | 0 |
| 30 Sep 19 | 78,929 | 9,262 | 19,855 | 0 |
| 30 Jun 19 | 75,478 | 8,098 | 19,237 | 0 |
| 31 Mar 19 | 73,572 | 7,605 | 18,728 | 0 |
| 31 Dec 18 | 70,157 | 6,602 | 17,762 | 0 |
| 30 Sep 18 | 68,318 | 6,293 | 17,412 | 0 |
| 30 Jun 18 | 67,788 | 6,955 | 17,212 | 0 |
| 31 Mar 18 | 63,918 | 6,309 | 16,555 | 0 |
| 31 Dec 17 | 60,044 | 7,009 | 15,102 | 0 |
| 30 Sep 17 | 57,285 | 7,626 | 14,699 | 0 |
| 30 Jun 17 | 55,019 | 7,248 | 14,245 | 0 |
| 31 Mar 17 | 56,875 | 8,920 | 13,910 | 0 |
| 31 Dec 16 | 56,933 | 7,732 | 13,497 | 0 |
| 30 Sep 16 | 54,992 | 7,267 | 12,977 | 0 |
| 30 Jun 16 | 52,419 | 7,108 | 9,430 | 0 |
| 31 Mar 16 | 49,248 | 7,416 | 11,699 | 0 |
| 31 Dec 15 | 47,975 | 8,189 | 15,267 | 220 |
| 30 Sep 15 | 44,556 | 7,227 | 15,252 | 291 |
| 30 Jun 15 | 40,459 | 5,781 | 11,940 | 150 |
| 31 Mar 15 | 37,434 | 3,916 | 9,032 | 0 |
| 31 Mar 14 | 31,191 | 4,353 | 10,466 | 210 |
Kwaliteitswinsten: ALKEM heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (16.5%) ALKEM } zijn hoger dan vorig jaar (11.6%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van ALKEM is de afgelopen 5 jaar met 6.9% per jaar gegroeid.
Versnelling van de groei: De winstgroei van ALKEM over het afgelopen jaar ( 48.1% ) overtreft het 5-jarig gemiddelde ( 6.9% per jaar).
Winst versus industrie: De winstgroei ALKEM over het afgelopen jaar ( 48.1% ) overtrof de Pharmaceuticals -sector 20.4%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 18.1% ) van ALKEM wordt als laag beschouwd.